A New Milestone in Obesity Treatment
Recent clinical trial results show that increasing the dosage of Wegovy, a weight-loss drug containing semaglutide, can lead to striking results. Participants given a weekly dose of 7.2 mg—three times higher than the currently approved 2.4 mg dose—achieved dramatic reductions in body weight. Over a period of 72 weeks, many volunteers lost between 20 and 21 percent of their body weight, and around one-third achieved weight loss of 25 percent or more.
Standard Versus High Dose
For comparison, patients on the standard 2.4 mg dose typically lost around 17.5 percent of their weight under similar conditions. The placebo group, which received lifestyle advice alone, saw far smaller improvements. This stark difference suggests that higher doses of semaglutide could push results into ranges previously thought achievable only through bariatric surgery. However, in people with Type 2 diabetes, weight loss was lower overall, with around 13 percent reduction at the high dose and about 10 percent at the standard dose.
Side Effects and Safety Considerations
The trials also highlighted the trade-offs of higher dosing. Gastrointestinal issues such as nausea and diarrhea were the most common side effects and appeared more frequently at the 7.2 mg level. A small number of participants discontinued treatment because of these problems. Importantly, no new major safety concerns were reported, though researchers emphasize that longer-term studies are needed to fully understand the risks.
The Bigger Picture
The ability of high-dose Wegovy to deliver weight loss on par with surgical methods marks an important step forward in obesity care. If these results hold in real-world settings, the treatment could provide a less invasive alternative for patients who have not met their goals with standard doses. For now, the findings underline the potential of semaglutide to transform the treatment landscape for obesity and related health conditions.
